Fukushima Toshihiro, Yoshio Nobuyuki, Noto Yutaka, Kida Hiroshi
National Kanazawa Hospital, Japan.
Int J Hematol. 2002 Feb;75(2):178-81. doi: 10.1007/BF02982024.
We report a case of acute myelogenous leukemia (AML) with MLL (myeloid-lymphoid leukemia or mixed-lineage leukemia) gene rearrangement after exposure to tegafur/uracil. Cytogenetic and clinical findings in this patient: t(11;17) (q23;q25), AML-M4 morphology, development of AML within a short latent period after first exposure to tegafur/uracil, and good response to remission induction chemotherapy but short remission duration, have been considered typical features of therapy-related acute myelogenous leukemia (t-AML) after exposure to topoisomerase II-targeting agents. This case report suggests that t-AML may develop after exposure to tegafur/uracil and that MLL gene rearrangement may not necessarily be specific to t-AML after exposure to topoisomerase II-targeting agents.
我们报告一例急性髓系白血病（AML）患者，其在接受替加氟/尿嘧啶治疗后出现MLL（髓系-淋巴系白血病或混合谱系白血病）基因重排。该患者的细胞遗传学和临床特征包括：t(11;17) (q23;q25)、AML-M4形态、首次接触替加氟/尿嘧啶后在短潜伏期内发生AML、对缓解诱导化疗反应良好但缓解期短，这些特征被认为是接触拓扑异构酶II靶向药物后治疗相关急性髓系白血病（t-AML）的典型特征。本病例报告表明，接触替加氟/尿嘧啶后可能发生t-AML，且MLL基因重排不一定是接触拓扑异构酶II靶向药物后t-AML所特有的。
